Patients
NMOSD
NEUROMYELITIS OPTICA
The main eligibility criteria for this study were an age of 18–75 years; a diagnosis of NMOSD, according to the 2015 International Panel for Neuromyelitis Optica Diagnosis criteria;Patients with rituximab treatment within 5 months, or plasma exchange and immunoglobulin treatment within 4 weeks prior to screening were not enrolled. Immunosuppressants and oral corticosteroids were stopped before lymphodepletion. Detailed description is provided in the study protocol (